SCHEMBL6087108

SCHEMBL6087108

CCN1C(=O)CS/C1=C(\C#N)c1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 6/20 0.62
▸ KMT2A Q03164 6/20 0.62
▸ HSD17B10 Q99714 2/20 0.62
▸ MAPT P10636 2/20 0.62
▸ ALDH1A1 P00352 4/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ GSK3A P49840 4/20 0.43
▸ GSK3B P49841 4/20 0.43
▸ GAA P10253 1/20 0.40
▸ USP2 O75604 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ THRB P10828 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.36
▸ DHODH Q02127 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ ATM Q13315 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6087113 1.00 MEN1 (0.62) MEN1KMT2AHSD17B10MAPTALDH1A1
SCHEMBL13897542 0.87 KMT2A (0.51) MEN1KMT2AHSD17B10MAPTALDH1A1
SCHEMBL13899791 0.87 KMT2A (0.51) MEN1KMT2AHSD17B10MAPTALDH1A1
SCHEMBL13897767 0.85 KMT2A (0.50) MEN1KMT2AHSD17B10MAPTALDH1A1
SCHEMBL13899685 0.85 KMT2A (0.50) MEN1KMT2AHSD17B10MAPTALDH1A1
SCHEMBL6086606 0.83 MEN1 (0.59) MEN1KMT2AHSD17B10MAPTALDH1A1
SCHEMBL6086601 0.83 MEN1 (0.59) MEN1KMT2AHSD17B10MAPTALDH1A1
SCHEMBL13897921 0.83 KMT2A (0.50) MEN1KMT2AHSD17B10MAPTALDH1A1
SCHEMBL13897706 0.81 MEN1 (0.54) MEN1KMT2AHSD17B10MAPTALDH1A1
SCHEMBL13899605 0.81 MEN1 (0.54) MEN1KMT2AHSD17B10MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060079503-A1 Thiazolidinones and the use therof as polo-like kinase inhibitors SCHERING AKTIENGESELLSCHAFT 2006-04-13 — — US disclosed
CN-1649853-A Thiazolidinones compound, its preparing method and use as medicine SCHERING AG (DE) 2005-08-03 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079503-A1 Thiazolidinones and the use therof as polo-like kinase inhibitors PLK4, PLK2, PLK3 MEN1 3800/4885KMT2A 3723/4885HSD17B10 1445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback